Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to $51.3 million.

  • Silence Therapeutics' Cash from Investing Activities rose 234.48% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.5 million, marking a year-over-year increase of 181.57%. This contributed to the annual value of -$22.0 million for FY2024, which is 213.85% down from last year.
  • Latest data reveals that Silence Therapeutics reported Cash from Investing Activities of $51.3 million as of Q3 2025, which was up 3,383.55% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Cash from Investing Activities ranged from a high of $66.1 million in Q4 2024 and a low of -$49.9 million during Q1 2024.
  • Over the past 3 years, Silence Therapeutics' median Cash from Investing Activities value was -$43,000 (recorded in 2024), while the average stood at $386,133.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 52,887.24% in 2023, then slumped by 32,177.59% in 2024.
  • Silence Therapeutics' Cash from Investing Activities (Quarterly) stood at $6.0 million in 2021, then plummeted by 420.80% to -$19.3 million in 2022, then soared by 102.46% to $474,120 in 2023, then spiked by 13,846.89% to $66.1 million in 2024, then spiked by 234.48% to $51.3 million in 2025.
  • Its Cash from Investing Activities was $51.3 million in Q3 2025, compared to -$1.6 million in Q2 2025 and -$44.4 million in Q1 2025.